OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 100,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The stock was acquired at an average price of $1.65 per share, for a total transaction of $165,000.00. Following the purchase, the chief executive officer now owns 213,751,448 shares of the company’s stock, valued at approximately $352,689,889.20. This represents a 0.05 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, March 28th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.70 per share, for a total transaction of $255,000.00.
• On Monday, March 17th, Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.74 per share, with a total value of $348,000.00.
• On Friday, February 28th, Phillip Md Et Al Frost purchased 67,434 shares of OPKO Health stock. The stock was bought at an average price of $1.71 per share, with a total value of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock. The shares were bought at an average price of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The stock was bought at an average price of $1.48 per share, for a total transaction of $740,000.00.

OPKO Health Price Performance

OPK opened at $1.66 on Wednesday. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The company’s 50-day moving average price is $1.69 and its 200 day moving average price is $1.58. OPKO Health, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $2.04. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -8.74 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million for the quarter, compared to analysts’ expectations of $155.42 million. As a group, sell-side analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Hedge Funds Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently modified their holdings of OPK. Millennium Management LLC increased its holdings in shares of OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after acquiring an additional 2,112,382 shares during the period. Northern Trust Corp increased its stake in shares of OPKO Health by 4.7% in the fourth quarter. Northern Trust Corp now owns 3,697,774 shares of the biotechnology company’s stock valued at $5,436,000 after purchasing an additional 164,847 shares during the period. Lazard Asset Management LLC raised its holdings in shares of OPKO Health by 143.6% during the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock valued at $3,746,000 after buying an additional 1,502,342 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of OPKO Health by 136.1% during the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock worth $2,422,000 after buying an additional 949,671 shares during the period. Finally, Nuveen Asset Management LLC grew its holdings in OPKO Health by 42.3% in the 4th quarter. Nuveen Asset Management LLC now owns 1,432,404 shares of the biotechnology company’s stock worth $2,106,000 after buying an additional 425,484 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Barrington Research reissued an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a report on Wednesday, March 12th. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. Finally, HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, March 19th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.